Neuromuscular Blocking Drugs

Correct Answer

B — Succinylcholine

Rationale

Succinylcholine is the only depolarizing neuromuscular blocking drug in clinical use. It acts as an agonist at the nicotinic acetylcholine receptor, persistently depolarizing the motor end plate and producing flaccid paralysis through a mechanism entirely distinct from all other neuromuscular blocking drugs. Vecuronium, rocuronium, and pancuronium are all nondepolarizing neuromuscular blocking drugs — they act as competitive antagonists at the nicotinic acetylcholine receptor and do not depolarize the end plate.

Correct Answer

C — Neostigmine

Rationale

Neostigmine is an anticholinesterase agent — it inhibits acetylcholinesterase at the neuromuscular junction, allowing acetylcholine to accumulate and compete with nondepolarizing blocking drugs at the nicotinic receptor. Sugammadex is a selective encapsulating reversal agent, not an anticholinesterase — it belongs to a different pharmacological class. Atropine is an antimuscarinic drug administered alongside neostigmine to prevent muscarinic side effects; it has no reversal activity at the neuromuscular junction. Dantrolene is the specific treatment for malignant hyperthermia and is not a reversal agent for neuromuscular block.

Correct Answer

A — Atropine

Rationale

Atropine is an antimuscarinic drug — it blocks muscarinic acetylcholine receptors throughout the body. When neostigmine is given to reverse nondepolarizing neuromuscular block, it raises acetylcholine at all synapses, including muscarinic ones, which can cause dangerous bradycardia and bronchospasm. Atropine is given to prevent these muscarinic effects. Succinylcholine is the depolarizing neuromuscular blocking drug, not a reversal-pairing agent. Neostigmine and pyridostigmine are both anticholinesterase agents — they belong to the class that requires antimuscarinic protection, not the antimuscarinic class itself.

Correct Answer

D — Pancuronium

Rationale

Pancuronium is the prototype long-acting nondepolarizing neuromuscular blocking drug, with a duration of action of 60 to 90 minutes or longer. Rocuronium and vecuronium are both classified as intermediate-acting agents, with durations of approximately 25 to 40 minutes. Mivacurium is a short-acting nondepolarizing agent with a duration of approximately 15 to 20 minutes, metabolized by plasma cholinesterase.

Correct Answer

B — Sugammadex

Rationale

Sugammadex is a modified cyclodextrin — a ring-shaped molecule classified as a selective encapsulating reversal agent. It captures rocuronium and vecuronium molecules directly in the plasma, forming an inactive complex that is excreted renally. This mechanism is distinct from anticholinesterase reversal: sugammadex does not inhibit acetylcholinesterase and does not raise acetylcholine levels. Neostigmine and pyridostigmine are anticholinesterase agents — a different reversal class requiring antimuscarinic pretreatment. Atropine is an antimuscarinic drug, not a reversal agent for neuromuscular block.

Correct Answer

C — Dantrolene

Rationale

Dantrolene is the specific pharmacological treatment for malignant hyperthermia — it is the only drug classified in this role. It must be given immediately when malignant hyperthermia is recognized, and its absence from a clinical setting where triggering agents are used represents a serious safety gap. Neostigmine is an anticholinesterase reversal agent for nondepolarizing neuromuscular block. Atropine is an antimuscarinic drug used to prevent muscarinic side effects of neostigmine. Succinylcholine is one of the trigger agents for malignant hyperthermia in susceptible patients, not the treatment.

Correct Answer

B — They occupy nicotinic receptor binding sites without activating the channel, so no end-plate depolarization occurs

Rationale

Nondepolarizing neuromuscular blocking drugs are competitive antagonists — they bind to the acetylcholine binding sites on the nicotinic receptor without opening the ion channel. Because no channel opening occurs, the end-plate membrane is never depolarized, no action potentials are generated in the muscle fiber, and no fasciculations appear. Fasciculations with succinylcholine arise because it is a receptor agonist that briefly activates channels across all motor end plates simultaneously before persistent depolarization blocks transmission. Nondepolarizing agents do not activate presynaptic voltage-gated sodium channels before reaching the receptor — that is not a mechanism of either drug class. Nondepolarizing agents act postsynaptically at the receptor, not presynaptically on acetylcholine release. Option D describes a partial agonist pattern that does not apply to nondepolarizing neuromuscular blocking drugs.

Correct Answer

D — Succinylcholine activates nicotinic receptors and depolarizes the end plate, then persistent depolarization inactivates surrounding voltage-gated sodium channels

Rationale

Succinylcholine is a nicotinic receptor agonist. When it binds the receptor, ion channels open and the end-plate membrane depolarizes. This initial depolarization spreads as action potentials throughout the muscle, producing the visible fasciculations. Unlike acetylcholine, succinylcholine is not rapidly hydrolyzed at the junction, so it persists and maintains end-plate depolarization. The voltage-gated sodium channels adjacent to the end plate, which must repolarize before they can open again, remain inactivated as long as the membrane is depolarized. The muscle cannot respond to subsequent nerve impulses and enters flaccid paralysis — phase I block. Options A and C describe mechanisms that do not apply to succinylcholine: it acts postsynaptically at the nicotinic receptor and does not reduce presynaptic acetylcholine release. Option B describes sarcoplasmic reticulum calcium channel activation, which is the pathophysiology of malignant hyperthermia rather than phase I depolarizing block.

Correct Answer

A — The normal end-plate potential is three to four times larger than the minimum needed to trigger a muscle action potential, providing a large excess amplitude that partial block must overcome

Rationale

The neuromuscular junction operates with a built-in safety margin: the end-plate potential generated by a normal nerve impulse is roughly three to four times the amplitude needed to fire the muscle. When a nondepolarizing blocking drug occupies a fraction of receptors, the remaining unblocked receptors still generate an end-plate potential that exceeds the firing threshold. It is only when enough receptors are occupied — approximately 70 to 80 percent — that the end-plate potential falls below the threshold for a muscle action potential and measurable weakness appears. Complete paralysis requires approximately 90 to 95 percent occupancy. Compensatory increases in presynaptic acetylcholine release do not occur to a clinically significant degree in this context. Extrajunctional receptors are not normally expressed at the motor end plate and do not serve a compensatory role in healthy innervated muscle.

Correct Answer

C — Neostigmine inhibits acetylcholinesterase, allowing acetylcholine to accumulate in the synaptic cleft and compete with vecuronium at the nicotinic receptor

Rationale

Neostigmine inhibits acetylcholinesterase — the enzyme that rapidly hydrolyzes acetylcholine in the synaptic cleft. When acetylcholinesterase is inhibited, acetylcholine released by each nerve impulse persists longer in the cleft and accumulates to higher concentrations. This elevated acetylcholine concentration shifts the competitive equilibrium at the nicotinic receptor in favor of the natural transmitter, progressively displacing the nondepolarizing blocking drug from receptor binding sites and restoring transmission. Neostigmine does not bind vecuronium directly — that encapsulation mechanism belongs to sugammadex. Neostigmine does not increase presynaptic acetylcholine synthesis. Neostigmine does not directly activate nicotinic receptors.

Correct Answer

B — Each successive stimulus depletes releasable acetylcholine, reducing competition against rocuronium at the receptor; succinylcholine block does not depend on this acetylcholine release mechanism

Rationale

Nondepolarizing block is competitive — the degree of block at any moment reflects the ratio of blocking drug to acetylcholine at the receptor. With each successive train-of-four stimulus, the nerve terminal releases acetylcholine from its immediately releasable pool, but that pool is not fully replenished in the 500-millisecond interval between stimuli. As the pool shrinks, less acetylcholine is available to compete with the blocking drug, so each successive twitch encounters a relatively stronger block — producing fade. Presynaptic nicotinic autoreceptors do contribute to fade — nondepolarizing agents block these autoreceptors and thereby reduce the facilitation of acetylcholine release that normally sustains the releasable pool across repeated stimuli — but the primary and dominant mechanism driving fade is progressive depletion of the immediately releasable acetylcholine pool with each successive impulse, not autoreceptor blockade alone. Succinylcholine holds the end plate in a persistently depolarized state regardless of how much acetylcholine the nerve terminal releases; its block does not depend on the competitive acetylcholine-drug balance, so no fade occurs. Rocuronium does not accumulate with repeated stimulation. Succinylcholine does not inhibit acetylcholinesterase.

Correct Answer

D — The end plate is already depolarized by succinylcholine; raising acetylcholine concentration cannot repolarize it, and the accumulated acetylcholine further prolongs the depolarized state

Rationale

Anticholinesterase reversal works by raising acetylcholine concentration so it can compete the nondepolarizing drug off the receptor — but this strategy requires a receptor and membrane that are capable of returning to normal function once the blocking drug is displaced. In phase I succinylcholine block, succinylcholine has already activated the receptor and the end plate is persistently depolarized. There is nothing for elevated acetylcholine to compete against in a meaningful sense; the block is not competitive. Raising acetylcholine by inhibiting acetylcholinesterase adds more agonist activity to an already-depolarized membrane, prolonging and deepening the block rather than reversing it. Neostigmine inhibits acetylcholinesterase, not plasma cholinesterase (the enzyme that metabolizes succinylcholine), though this distinction does not change the core reasoning. Muscarinic receptors are not present at the motor end plate — neostigmine's muscarinic effects occur elsewhere in the body.

Correct Answer

A — A single nondepolarizing blocking drug molecule occupying one site prevents channel opening even when the other site is occupied by acetylcholine

Rationale

Because both acetylcholine binding sites must be occupied simultaneously for the nicotinic ion channel to open, a single nondepolarizing blocking drug molecule at one site is sufficient to prevent channel opening — even if the other site still has acetylcholine bound. The receptor cannot open with one site blocked, regardless of what occupies the other. This means that nondepolarizing agents are pharmacologically efficient: each bound molecule silences one receptor completely, contributing to the competitive block. Two blocking drug molecules are not required to block a single receptor. The dual-site requirement is about what is needed for activation, not about what is needed for blockade — one antagonist molecule at one site is sufficient to prevent the required dual agonist occupancy.

Correct Answer

C — Denervation and injury cause upregulation of nicotinic receptors across the entire muscle surface, so succinylcholine activates a vastly expanded receptor population and triggers massive potassium efflux

Rationale

Under normal conditions, nicotinic acetylcholine receptors are confined to the motor end plate. When muscle is denervated, burned, crushed, or immobilized, the fiber upregulates nicotinic receptors across the entire extrajunctional membrane surface as a compensatory response to loss of normal neural input. These extrajunctional receptors open more readily and close more slowly than normal junctional receptors. When succinylcholine is given, it activates not just the end-plate receptors but the entire expanded population across the muscle surface, producing a massive simultaneous efflux of potassium from skeletal muscle cells throughout the body. Serum potassium can rise 5 to 10 milliequivalents per liter or more — sufficient to cause ventricular fibrillation. Additive potassium from necrotic tissue and impaired renal clearance do not account for the magnitude or speed of the potassium rise seen in this setting. Plasma cholinesterase reduction prolongs succinylcholine action through a separate mechanism and does not explain the catastrophic potassium surge seen with extrajunctional upregulation.

Correct Answer

B — Succinylcholine activates the nicotinic receptor and depolarizes the end plate, producing fasciculations; persistent depolarization then inactivates surrounding voltage-gated sodium channels, producing flaccid paralysis

Rationale

Succinylcholine is a nicotinic acetylcholine receptor agonist — it binds and opens the ion channel, depolarizing the end-plate membrane. This initial depolarization spreads as action potentials throughout skeletal muscle, producing the visible fasciculations. Unlike acetylcholine, succinylcholine resists hydrolysis by acetylcholinesterase in the synaptic cleft and persists at the receptor, maintaining continuous end-plate depolarization. The voltage-gated sodium channels adjacent to the end plate require repolarization before they can reopen; as long as the membrane remains depolarized by succinylcholine, these channels stay inactivated and the muscle cannot fire again. The result is flaccid paralysis despite ongoing receptor occupancy — phase I block. Succinylcholine does not inhibit acetylcholinesterase and does not act as a competitive antagonist; those mechanisms belong to other drug classes.

Correct Answer

D — Autoantibodies destroy nicotinic receptors at the motor end plate, reducing receptor density so that a standard dose of rocuronium occupies a much larger fraction of the available receptor pool

Rationale

In myasthenia gravis, autoantibodies target the nicotinic acetylcholine receptor at the motor end plate, causing receptor internalization and destruction. In severely affected patients, receptor numbers may be reduced by 70 to 80 percent from normal. These patients already operate close to the threshold for neuromuscular transmission failure, with little safety margin remaining. When a nondepolarizing blocking drug is given, even a standard dose occupies a much larger fraction of the already-depleted receptor pool than it would in a patient with a normal complement of receptors — producing disproportionately deep and prolonged block. Myasthenia gravis does not impair acetylcholinesterase activity. Extrajunctional receptor upregulation occurs in denervation and injury, not in myasthenia gravis — and would actually provide more receptor targets rather than increasing sensitivity. Rocuronium is eliminated by biliary excretion, not renal clearance, and myasthenia gravis does not affect this pathway.

Correct Answer

A — Prolonged succinylcholine exposure has caused phase II block, in which the receptor undergoes a conformational change to a desensitized state and the block begins to resemble nondepolarizing block

Rationale

With prolonged or repeated succinylcholine dosing, the initial phase I block — characterized by uniform depression of all four train-of-four twitches with no fade — can shift to phase II block. In phase II block, the end-plate membrane partially repolarizes and the nicotinic receptor undergoes a conformational change toward a desensitized state in which it can no longer respond normally to agonist binding. The block begins to resemble nondepolarizing block in its characteristics: fade appears on train-of-four stimulation. The mechanism of phase II block is distinct from simple competitive antagonism — succinylcholine does not become a competitive antagonist. Plasma cholinesterase exhaustion is not a recognized mechanism of phase II block; the enzyme circulates in large quantities and is not depleted by a continuous infusion. Extrajunctional receptor upregulation from immobilization requires days to develop and would produce hyperkalemia risk rather than a change in train-of-four fade pattern.

Correct Answer

C — Denervation following spinal cord injury caused upregulation of nicotinic acetylcholine receptors across the entire muscle surface; succinylcholine activated this expanded receptor population, producing massive potassium efflux sufficient to cause ventricular fibrillation

Rationale

When skeletal muscle is deprived of its normal nerve supply — as occurs in spinal cord injury, stroke with hemiplegia, or peripheral nerve damage — the muscle fiber responds by upregulating nicotinic acetylcholine receptors across the entire extrajunctional membrane surface. These extrajunctional receptors open more readily and close more slowly than normal junctional receptors. When succinylcholine is given to a patient with widespread denervation, it activates the vastly expanded receptor population across the entire muscle surface simultaneously, producing massive, synchronized potassium efflux from skeletal muscle throughout the body. Serum potassium can rise 5 to 10 milliequivalents per liter or more within minutes — sufficient to produce ventricular fibrillation. This risk is present from approximately 24 to 48 hours after denervating injury and persists for as long as denervation remains. Succinylcholine does not activate cardiac muscarinic receptors to a clinically significant degree. Spinal cord injury does not impair renal potassium handling in a manner that would cause this degree of hyperkalemia. Option D describes malignant hyperthermia — a different pharmacogenetic crisis with a distinct mechanism.